Fig 1: Exogenetic overexpression of PRIM2 recovered the inhibitory effects of DHA on proliferation and colony formation in lung cancer cells. (A) The overexpression of PRIM2 was confirmed by Western blotting assay. (B–D) The cell viability and colony formation ability of NCI-H23 cells were detected by CCK-8 assay and colony formation assay. (E–G) Measurement of cellular GSH, cellular ROS and mitochondrial MDA in NCI-H23 cells which were treated with 60 μM DHA and transfected with PRIM2 OE plasmid. (H) The protein expressions of SLC7A11 and β-catenin were analyzed by Western blotting assay. The experiments were repeated for three times. Compared with 0 μM DHA treated cells: ***p < 0.001; Compared with 60 μM DHA treated and empty vector transfected cells, ##p < 0.01, ###p < 0.001.
Fig 2: DHA downregulates the PRIM2 expression and silencing PRIM2 inhibits the proliferation and colony formation and induces ferroptosis of lung cancer cells. (A and B) The mRNA expression of PRIM2 was detected by qRT-PCR. (C) The protein expression of PRIM2 was detected by Western blotting assay. (D and E) The expression level of PRIM2 in lung cancer cells was analyzed by using CCLE database and detected by qRT-PCR. (F and G) The efficiency of PRIM2 silencing was analyzed by qRT-PCR and Western blotting assays. (H) The cell viabilities of NCI-H23 and XWLC-05 cells which were transfected with PRIM2 siRNAs were detected by CCK-8 assay. (I) The cell deaths of NCI-H23 and XWLC-05 cells were analyzed by trypan blue exclusion assay. (J) The colony formation abilities of NCI-H23 and XWLC-05 cells were analyzed by colony formation assay. The experiments were repeated for three times. Compared with 0 μM DHA treated cells or Negative control group (NC): **p < 0.01, ***p < 0.001.
Fig 3: DHA inhibits the tumor growth in vivo. (A) DHA treatment clearly inhibited the tumor growth compared with the control group. (B) The expressions of PRIM2, SLC7A11 and β-catenin were analyzed by Western blotting assay. Compared with Negative control group (NC): **p < 0.01.
Fig 4: DHA and loss of PRIM2 reduce the GSH level and increase the cellular lipid ROS and mitochondrial MDA levels, and downregulate the expressions of SLC7A11 and β-catenin in lung cancer cells. (A–C) Measurement of cellular GSH, cellular ROS and mitochondrial MDA in DHA treated NCI-H23 and XWLC-05 cells. (D–F) Measurement of cellular GSH, cellular ROS and mitochondrial MDA in PRIM2 siRNAs transfected NCI-H23 and XWLC-05 cells. (G and H) The protein expressions of SLC7A11 and β-catenin were analyzed by Western blotting assay. The experiments were repeated for three times. Compared with 0 μM DHA treated cells or Negative control group (NC): **p < 0.01, ***p < 0.001; Compared with 40 μM/60 μM DHA treated cells or only PRIM2 siRNAs transfected cells, ##p < 0.01, ###p < 0.001.
Fig 5: Loss of PRIM2 sensitizes NCI-H23 cells to DHA therapy. (A–C) The cell viability and colony formation ability of NCI-H23 cells were detected by CCK-8 assay and colony formation assay. (D–F) Measurement of cellular GSH, cellular ROS and mitochondrial MDA in NCI-H23 cells. (G) The protein expressions of SLC7A11 and β-catenin were analyzed by Western blotting assay. (H) The expression of PRIM2 in LUAD was analyzed by TCGA data using starBase database. The experiments were repeated for three times. Compared with 40 μM DHA treated and Negative control shRNA transfected cells: *p < 0.05, **p < 0.01, ***p < 0.001.
Supplier Page from Abcam for Anti-PRIM2 antibody